目的乙型肝炎病毒(hepatitis B virus,HBV)感染者在接受细胞毒性化疗或免疫抑制治疗时存在HBV再激活的风险。文中探讨HBV感染的消化道恶性肿瘤术后化疗患者化疗后HBV再激活及肝功能损害发生情况。方法回顾性分析102例合并HBV感染的胃癌和结、直肠癌术后患者HBV再激活情况,所有患者进行HBV血清学和生物化学检测。结果 102例患者有46.1%(47/102)出现肝功能异常,有40.2%(41/102)出现HBV再激活;41例HBV再激活患者中35例出现肝功能异常(85.4%),其中16例化疗剂量调整或推迟化疗,8例终止化疗。HBV再激活肝功能异常发生率(85.4%)高于未出现HBV再激活患者(19.7%,12/61),两者比较差异有统计学意义(P<0.01);化疗前检测HBV-DNA>103拷贝/ml患者HBV再激活发生率高于HBV-DNA<103拷贝/ml患者(60.0%vs 27.4%,P<0.01)。结论 HBV感染的消化道肿瘤术后患者接受化疗时存在HBV再激活并导致肝功能损害,化疗前HBV-DNA高者更易发生HBV再激活。
【英文摘要】
Objective Patients with hepatitis B virus( HBV) infection undergoing cytotoxic chemotherapy or immunologic suppression therapy face the risk of HBV reactivation. This study was to investigate HBV reactivation and liver damage in HBV-infected patients with digestive tract malignancy after postoperative chemotherapy. Methods We retrospectively analyzed 102 HBV-infected patients with gastric or colon and rectal cancer that received chemotherapy after surgery. We conducted serological and biochemical tests of H...